BioMed Central

Page 1 of 9

BMC Infectious Diseases

Research article

Seroprevalence and correlates of HIV, syphilis, and hepatitis B and C virus among intrapartum patients in Kabul, Afghanistan

Catherine S Todd*1, Malalay Ahmadzai2, Faridullah Atiqzai3, Suellen Miller4, Jeffrey M Smith5, Syed Alef Shah Ghazanfar4 and Steffanie A Strathdee1

Address: 1Division of International Health & Cross-Cultural Medicine, University of California, San Diego, La Jolla, California, USA, 2UNICEF, Afghanistan Office, UNAMA Compound, Kabul, Afghanistan, 3Ministry of Public Health, Islamic Republic of Afghanistan, Kabul, Afghanistan, 4Womens Global Health Imperative, University of California, San Francisco, San Francisco, California, USA and 5Jhpiego Corporation, Baltimore, Maryland, USA

Email: Catherine S Todd* - cstodd@ucsd.edu; Malalay Ahmadzai - mahmadzai@unicef.org; Faridullah Atiqzai - atikzaifarid@yahoo.com; Suellen Miller - SMiller@globall-health.ucsf.edu; Jeffrey M Smith - jsmith@jhpiego.net; Syed Alef Shah Ghazanfar - ghazanfar@yahoo.com; Steffanie A Strathdee - sstrathdee@ucsd.edu

* Corresponding author

Abstract

Background: Little current information is available for prevalence of vertically-transmitted infections among the Afghan population. The purpose of this study is to determine prevalence and correlates of human immunodeficiency virus (HIV), syphilis, and hepatitis B and C infection among obstetric patients and model hepatitis B vaccination approaches in Kabul, Afghanistan.

Methods: This cross-sectional study was conducted at three government maternity hospitals in Kabul, Afghanistan from June through September, 2006. Consecutively-enrolled participants completed an interviewer-administered survey and whole blood rapid testing with serum confirmation for antibodies to HIV, T. pallidum, and HCV, and HBsAg. Descriptive data and prevalence of infection were calculated, with logistic regression used to identify correlates of HBV infection. Modeling was performed to determine impact of current and birth dose vaccination strategies on HBV morbidity and mortality.

Results: Among 4452 women, prevalence of HBsAg was 1.53% (95% CI: 1.18 – 1.94) and anti-HCV was 0.31% (95% CI: 0.17 – 0.53). No cases of HIV or syphilis were detected. In univariate analysis, HBsAg was associated with husband's level of education (OR = 1.13, 95% CI: 1.01 – 1.26). Modeling indicated that introduction of birth dose vaccination would not significantly reduce hepatitis-related morbidity or mortality for the measured HBsAg prevalence.

Conclusion: Intrapartum whole blood rapid testing for HIV, syphilis, HBV, and HCV was acceptable to patients in Afghanistan. Though HBsAg prevalence is relatively low, periodic assessments should be performed to determine birth dose vaccination recommendations for this setting.
Background
Testing for human immunodeficiency virus (HIV), syphilis, and hepatitis B surface antigen (HBsAg) in pregnancy and labor is medically indicated to prevent vertical transmission. Prevalence of these infections among the antenatal population may be a reliable indicator of general population prevalence and determinant of vaccination policy [1-3]. The intrapartum period may be the only clinical access point for the antenatal population in limited resource settings. Successful interventions to prevent vertical transmission linked to intrapartum rapid testing have been demonstrated in a variety of limited resource settings [4,5]. One such intervention is birth dose hepatitis B vaccine. Recommendations for birth dose vaccination are determined by antenatal prevalence of hepatitis B e antigen (HBeAg) and to some degree by HBsAg in settings where HBeAg prevalence is unknown [6]. Risk of vertical transmission should not be underestimated in settings where HBeAg is relatively low or assumed to be low; Chauvin et al. indicate that even in settings where HBeAg prevalence among mothers is relatively low (< 20%), the number of chronic carriers resulting from lack of birth dose vaccination exceeds 500/100,000, the threshold for instituting other neonatal immunization programs, such as poliomyelitis [7]. In many settings, resources do not exist to assess HBeAg prevalence so vaccination policy may be made on HBsAg prevalence alone.

Afghanistan has an evolving health infrastructure and many barriers remain to accessible care, including ongoing conflict and a shortage of trained providers. Blood donor data is the sole published source of population-based prevalence data. From March through December 2006, the Central Blood Banks in Afghanistan reported prevalence of transfusion-associated infections based on single screening test protocol [8]. For Kabul province, low prevalence of HIV antibody (0.0006%), syphilis-suggestive reaction (VDRL 1.1%), HBsAg (3.9%), and hepatitis C antibody (anti-HCV) (1.9%) was reported, with HBsAg prevalence suggesting intermediate prevalence [8]; see additional file 1]. For the last three years in Afghanistan, monovalent hepatitis B vaccine has been administered simultaneously with diphtheria-pertussis-tetanus (DPT) vaccine at two, four, and six months of life. In 2005, the DPT completion rate for the Kabul urban area was estimated to be 28.6% [9].

Hepatitis B virus (HBV) prevalence has also been reported among Afghan refugee populations outside of Afghanistan, with higher prevalence noted than that reported among Afghan blood donors [10,11]. Since 2002, the return of 4.8 million refugees, largely from neighboring countries with higher prevalence of HBV and hepatitis C virus (HCV) (e.g. Iran, Pakistan), raises concern that prevalence of hepatitis and other blood-borne infections within the country may increase [11]. Reliable general population prevalence is also needed to inform evolving vaccination and sexually transmitted infection (STI) prevention programs. The purposes of this study were to determine the prevalence and correlates of HIV, syphilis, and hepatitis B and C infection and to model the impact of various vaccination strategies at measured HBsAg prevalence among intrapartum patients in Kabul, Afghanistan.

Methods
Setting
Kabul, the capital of Afghanistan, had a population of approximately 2.5 million in 2005, with an estimated facility-based delivery rate for urban areas of 85.2% [9,12]. There are four public maternity hospitals in the city, providing free obstetric care locally and serving as regional referral centers for other facility- or home-based deliveries. At the time of the study, the three hospitals with highest delivery volumes in the previous quarter (Malalai, Rabia Balkhi, and Khair Khana) were included. Prior to enrollment, approval was obtained from the Afghan Ministry of Public Health and University of California, San Diego (Protocol #060083) institutional review boards. All study procedures were followed in accordance with the ethical standards of these review boards.

Participants
Eligibility for this cross-sectional study was confined to pregnant women admitted in stable medical condition; women with conditions requiring urgent medical intervention (e.g. eclampsia, hemorrhage), imminently delivering (cervical dilation ≥ 8 cm), or unable to provide informed consent were excluded. Potential participants were consecutively evaluated from June to September, 2006. Potential study participants either declining participation or ineligible for participation were enumerated and assessed by age or parity for comparison to enrolled participants.

Questionnaire Development
Questionnaires were developed with input from a local advisory board of reproductive health specialists in Kabul. Following pilot-testing and board review, the final questionnaire was edited, translated, and back-translated for accuracy. The instrument assessed demographics, socioeconomic status, and time spent outside the country, including prior refugee status. Past medical and obstetric history was queried, including number, site, year, and outcome of prior deliveries and prenatal care for the current pregnancy. Risk factors for sexually transmitted and blood-borne infections, such as drug use or number of therapeutic injections, were also assessed.
Enrollment Procedures
Study representatives were female medical providers (midwives and physicians) who were not employees of the study hospitals. Study representatives were trained in human subjects’ research, questionnaire administration, rapid testing, and pre and post-test counseling. Trained representatives were present in shifts to ensure 24 hour enrollment coverage. All women presenting for admission were assessed for study entry. Following medical evaluation and admission, eligible women were invited to accompany the study representative to a private room for informed consent; all women provided written informed consent prior to enrollment. Consented participants were assigned a study number, unlinked to any hospital identifiers, that was the sole identifier on all study materials.

Participants completed an interviewer-administered questionnaire. Pre-test counseling, whole blood rapid testing with finger stick specimen, and post-test counseling with provision of results were then performed. Following these activities, participants were escorted back to the labor ward. Participants who were too uncomfortable for interview or testing following consent were excused from the study (n = 3); those who were somewhat uncomfortable during interview had the interview suspended and testing performed, with the questionnaire completed after delivery. Free testing was the only compensation provided for participation.

Patient Testing and Prophylaxis
Rapid testing was performed with Abbott Determine® HIV 1/2, Syphilis TP, and HBsAg (Abbott Diagnostics Japan, Tokyo, Japan) and with Standard Diagnostics Anti-HCV (Standard Diagnostics Laboratories, Kyonggi-do, Korea). A second rapid test (OraSure OraQuick HIV 1/2®, OraSure Technologies, Bethlehem, PA) was available for tandem HIV testing, with Western Blot (HIV BLOT 2.2®, GeneLabs Diagnostics, Singapore) available for confirmation. Treponema pallidum particle agglutination (TPPA) assay (Fujirebio Diagnostics, Malvern, PA, USA) and rapid plasma reagin (RPR) (Spectra Diagnostics, Cairo, Egypt) were available for syphilis confirmation and clinical monitoring. All participants with positive rapid tests underwent intravenous sampling, from which serum was prepared and stored for confirmatory testing.

HBV was confirmed with a second, serum-based rapid test (Standard Diagnostics HBV, Standard Diagnostics Laboratories, Korea), as nucleic acid testing was not available. Use of the Determine® and Standard Diagnostics® rapid tests with sensitivities of 99.0% and 99.0% and specificities of 99.0% and 100.0%, respectively, have a positive predictive value (PPV) of 99.988%, assuming a baseline prevalence of HBsAg of 5.0% [13,14]. HCV antibody was confirmed with RIBA (RIBA 3.0 SI®, Chiron Corporation, Emeryville, CA, USA). All confirmatory testing was performed at the VCT Center in Kabul by trained laboratory personnel.

Participants with any positive rapid test (or two for HIV) were treated as presumptive positives and received intra- or post-partum prophylaxis. Protocols were in place for management of prevention of vertical transmission of HIV or HBV and maternal and neonatal syphilis, following international guidelines [15-17].

Analysis
Student’s T-test and the binomial probability test were used to compare participants and those ineligible or declining entry. Descriptive statistics were generated to further characterize the study population. Prevalence for each infection was calculated with confidence intervals based on the Poisson distribution for anti-HCV and HBsAg. The sample size was sufficient to determine at least a 28% difference in demographic and risk variables between HBsAg-positive and HBsAg-negative participants (P = 80%, two-sided alpha = 0.05). Correlates of HBsAg were assessed with univariable logistic regression. Data were entered and cleaned with EpiData 3.1 (EpiData Association, Odense, Denmark) and analyzed with Stata 8.0 (Stata Corp, College Station, Texas).

Hepatitis B vaccination modeling
The Hepatitis B Disease Burden and Vaccination Model Version 1.2 from the Centers for Disease Control and Prevention was used to estimate hepatitis cases averted for several vaccination strategies, given measured HBsAg seroprevalence [18]. The model requires input of prevalence of maternal hepatitis B e antigen (HBeAg) and child and adult hepatitis B core antibody (anti-HBc) among those positive for HBsAg, for which there is no data from Kabul. A small study done among Afghan refugees in Iran reported that, of women testing positive for HBsAg, no women had HBeAg [11]. However, due to the small sample size, we elected to use data from other sources for this calculation. India was the country of closest geographic proximity with published HBeAg prevalence among antenatal populations positive for HBsAg, ranging between 7.8% and 18.0%; [19-21] we used the estimate of 12.5% for presumed HBeAg prevalence among women testing positive for HBsAg in the model. The model population was the birth cohort for the maternity hospitals of Kabul for 2006 less the probable neonatal and infant deaths (based on national infant mortality rate, resultant n = 45,090). Estimates of anti-HBc of 30% for children and 60% for adults were used to complete the model, which are identical to those used for a model created by the World Health Organization in development of a HBV vaccination strategy for Afghanistan [22].
Results
Enrollment comprised 4,452 participants, with 1,179 women ineligible and 153 declining participation. Reasons for ineligibility included imminent delivery (62.9%), emergent operative intervention (22.5%), hemorrhage (7.2%), non-reassuring fetal status (6.7%), or other reasons (e.g. eclampsia, 0.7%). Participants were younger (mean 25.74 vs. 27.70, p < 0.001) and had lower parity (mean 2.09 vs. 3.41, p < 0.001) than those ineligible. Women declining enrollment were of greater parity (mean = 3.06, p < 0.001), but did not differ significantly by age.

Demographic and healthcare access information is displayed in Table 1. Generally, participants were young, originated from Kabul province, and had little or no formal education. Regarding high risk behaviors, no participants reported personal non-medicinal drug use and only 2.0% (n = 90) reported drug use by their spouses, of whom 45.5% stated that their husbands had ever injected drugs. Few participants reported that their spouses had

Table 1: Descriptive Characteristics of Women Delivering in Government Hospitals between June and September, 2006 in Kabul, Afghanistan (n = 4452).

| Variable                                      | Mean  | Median | Range         |
|-----------------------------------------------|-------|--------|---------------|
| Age                                           | 25.74 years | 24 years | 14 – 48 years |
| Age at Marriage                               | 19.49 years | 18 years | 10 – 37 years |
| Number living in household                    | 7.36  | 5      | 1 – 40        |
| Ethnic Group (n = 4444)                       |       |        |               |
| Tajik                                         | 3158  | 71.1%  |               |
| Pashtun                                        | 339   | 7.6%   |               |
| Hazara                                         | 923   | 20.8%  |               |
| Other                                          | 24    | 0.5%   |               |
| Country of Birth (n = 4448)                   |       |        |               |
| Afghanistan                                   | 4420  | 99.3%  |               |
| Other                                          | 28    | 0.7%   |               |
| Province of Birth (n = 4422)                  |       |        |               |
| Kabul & surrounding provinces                 | 3492  | 79.0%  |               |
| Northern                                       | 406   | 9.2%   |               |
| Central                                        | 299   | 6.8%   |               |
| Eastern                                        | 172   | 3.9%   |               |
| Western                                        | 25    | 0.6%   |               |
| Southern                                       | 28    | 0.6%   |               |
| Lived outside Afghanistan in last 5 years (n = 4348): |       |        |               |
| Yes                                           | 1650  | 37.1%  |               |
| Educational Level (n = 4447)                  |       |        |               |
| No formal education                            | 2996  | 67.4%  |               |
| 1–2 years                                      | 179   | 4.0%   |               |
| Finished primary school                        | 404   | 9.1%   |               |
| Some secondary school                          | 326   | 7.3%   |               |
| Finished secondary school                      | 349   | 7.9%   |               |
| Some university                                | 113   | 2.5%   |               |
| Finished university                            | 80    | 1.8%   |               |
| Frequency Family Eats Meat (n = 4447)          |       |        |               |
| < Once weekly                                  | 361   | 8.1%   |               |
| Once weekly                                    | 1900  | 42.7%  |               |
| Twice weekly                                   | 1492  | 33.6%  |               |
| > Twice weekly                                 | 684   | 15.6%  |               |
| Usual Means of Transport (n = 4444)            |       |        |               |
| Public Bus                                     | 1848  | 41.6%  |               |
| Taxi                                           | 1366  | 30.7%  |               |
| Family Car                                     | 1175  | 26.4%  |               |
| On foot                                        | 39    | 0.9%   |               |
| Motorcycle                                     | 9     | 0.2%   |               |
| Horse cart                                     | 4     | 0.1%   |               |
| Seen medical provider this pregnancy (n = 3930) |       |        |               |
| Yes                                           | 3930  | 88.4%  |               |
| Number of Prior Pregnancies                   |       |        |               |
| 0                                             | 1495  | 33.6%  |               |
| 1                                             | 719   | 16.2%  |               |
| 2                                             | 653   | 14.7%  |               |
| 3                                             | 545   | 12.2%  |               |
| 4                                             | 364   | 8.2%   |               |
| 5                                             | 299   | 6.7%   |               |
| ≥ 6                                           | 377   | 8.4%   |               |
| Last Birth Attended (n = 2936)                 |       |        |               |
| Yes                                           | 2283  | 77.3%  |               |
engaged in extramarital sexual contact with either men or boys (0.2%, n = 7) or other women (0.7%, n = 30). Few participants had lived in a refugee camp (6.5%, n = 289) or had spouses that had been incarcerated (5.0%, n = 221). The majority had not received therapeutic injections from either a medical (75.0%, n = 3,333) or non-medical provider (99.1%, n = 4,405) in the last year.

No participants tested positive for either syphilis or HIV. Prevalence of HBsAg was 1.53% (95% CI: 1.18 – 1.94) and anti-HCV was 0.31% (95% CI: 0.17 – 0.53). There were two false positive HBsAg Determine® rapid tests; the second serum-based rapid test was negative (PPV = 97.1%). There were no participants testing positive for both HBsAg and anti-HCV. The absence or low prevalence of HIV, syphilis, and anti-HCV precluded subsequent analysis of correlates.

**Correlates of HBsAg**

Only spousal educational level was associated with HBsAg infection in univariate analysis (OR = 1.13, 95% CI: 1.01 – 1.26). When stratified by level of education, only those women whose husbands had finished university were more likely to have HBsAg, while women whose husbands had no formal education were less likely to have HBsAg (Table 2). There was no significant relationship detected between a positive HBsAg test and any other variable reflecting demographics, health care utilization, or high-risk behaviors for either the participant or her spouse in univariate analysis (data not shown).

**Hepatitis B Vaccination Modeling**

Based on measured prevalence of HBsAg, 1313 cases of chronic HBV would be averted with current vaccination practice (Table 3). Were birth dose vaccination introduced with 85% coverage, perinatal cases would be reduced by 27% (Table 4). However, cases of chronic hepatitis, hepatocellular carcinoma, or death from hepatic disease would not be significantly altered with birth dose vaccination (p = 0.11).

**Discussion**

This study is among the first to assess prevalence of HIV, syphilis, HBV, and HCV in an obstetric population in modern Afghanistan. HIV was not detected, corroborating low prevalence noted in other Afghan populations [[8] – see additional file 1;[23]]. Prevalence of both HBsAg and HCV were lower than those detected through the Central Blood Bank for Kabul province or among Afghan populations in refugee camps in Balochistan (i.e., the Northwest Frontier province of Pakistan) or in southwest Iran [[8] – see additional file 1; [10,11]]. The associations between HBsAg and therapeutic injections or markers of low socioeconomic status noted in among Afghan refugees and in other settings were not detected in the study population, perhaps because reported therapeutic injections in the last year were fairly uncommon or because low prevalence may have diminished the power to detect some associations [10,24,25]. Given the large number of Afghans repatriating from areas of higher hepatitis prevalence in the last five years, similar assessments should be considered in border areas where former refugee camp denizens often initially reside upon repatriation.

It is unclear why the highest spousal educational level was associated with hepatitis B. This relationship may reflect husbands educated in countries with greater hepatitis B prevalence who, following cessation of civil conflict, returned to Afghanistan, married, and transmitted the infection to their spouse. This relationship is similar to that between HIV and higher educational level in rural populations in Africa, where migration for education and possibly infection occurred [26]. In the Afghan context, adult hepatitis B transmission is likely to be iatrogenic or sexual and may predominantly affect the male population. A study assessing HBsAg seroprevalence among blood donors in Pakistan noted males were more likely to be infected than females; both this study and a study exclusively looking at first-time male blood donors noted that hepatitis B transmission likely occurred through unclean medical or shaving supplies [27,28]. We did not interview or test the spouses, but such an assessment may be indicated.

| Level of Husband's Education (n) | Maternal HBsAg n, (%) | OR, (95% CI) |
|----------------------------------|-----------------------|-------------|
| No formal education (n = 1937)   | 20, (1.03%)           | 0.54, (0.32 – 0.91) |
| 1 – 2 years of formal education (n = 97) | 1, (1.03%)     | 0.67, (0.09 – 4.85) |
| Completed primary school (grade 6) (n = 400) | 9, (2.25%)      | 1.56, (0.77 – 3.17) |
| Completed some secondary school (n = 505) | 12, (2.38%)     | 1.69, (0.90 – 3.18) |
| Completed secondary school (n = 905) | 15, (1.66%)     | 1.11, (0.62 – 1.98) |
| Completed some university (n = 225) | 0, (0%)         | ------       |
| Completed university or higher (n = 309) | 11, (2.90%)    | 2.10, (1.09 – 4.05) |
Screening for HIV and syphilis has been posited as optional in some low prevalence settings as resources expended on screening are not justified by the low number of infections detected [29]. However, analyses indicate that screening for HIV and syphilis is cost effective even in very low prevalence settings [30,31]. We did not detect any cases of HIV or syphilis among participants delivering in government hospitals, suggesting that scarce resources should not be diverted to screening at this time. However, generalization of our findings is limited as only women accessing care in government hospitals were assessed.

In the case of hepatitis B, it is reasonable to consider peripartum testing with birth dose vaccine and parental counseling to ensure completion of the vaccine series, as reported rates of likely vaccination series completion are sub-optimal [9]. Based on international recommendations on birth dose hepatitis B vaccination, modeling did not suggest a significant advantage in changing the current strategy [5,6,32]. However, due to the shifting population dynamics in Afghanistan, routine surveillance should be conducted as birth dose vaccination will be recommended if antenatal prevalence of HBsAg reaches 2% [5,33].

This study has a number of important limitations. First, the population consists only of those women able to access care, likely those of higher socioeconomic status. Because hepatitis B has been associated with lower socioeconomic status, the prevalence reported here may underestimate the true prevalence among reproductive-aged women in Kabul. Second, there may have been underreporting of risky behaviors or other socially-desirable responses in this interviewer-administered survey. Further, as the questionnaire was administered during labor, there may have been response truncation due to discomfort. We attempted to minimize this by conducting all interviews in a private setting with a female interviewer. However, interviewer administration was the only feasible means of data collection, due to low literacy and the prohibitive cost of audio computer-assisted self-interview

### Table 3: Hepatitis B acquisition and future burden estimates for infants born in government maternity hospitals with current vaccination programming with the DPT series in Kabul, Afghanistan.

|                                | Number Without Program | Number With Program | Number Prevented | Percent Reduction |
|--------------------------------|------------------------|---------------------|------------------|------------------|
| **A. Disease Events Prevented (Future burden)** |                        |                     |                  |                  |
| Total HBV infections           | 27,054                 | 19,735              | 7,319            | 27%              |
| Acute symptomatic hepatitis B cases | 5,400                  | 3,933               | 1,467            | 27%              |
| Chronic HBV infections         | 4,937                  | 3,625               | 1,313            | 27%              |
| HBV-related deaths:            |                        |                     |                  |                  |
| Acute hepatitis B              | 23                     | 17                  | 6                | 27%              |
| Cirrhosis                      | 268                    | 197                 | 71               | 27%              |
| Hepatocellular carcinoma       | 170                    | 125                 | 45               | 27%              |
| Total Deaths                   | 460                    | 338                 | 123              | 27%              |
| **B. Number of Infections by Age at Acquisition of Infection (Future burden)** |                        |                     |                  |                  |
| Perinatal Infection            | 117                    | 117                 | 0                | 0%               |
| Early Childhood Infection      | 13,410                 | 9,766               | 3,643            | 27%              |
| Late Infection                 | 13,527                 | 9,852               | 3,675            | 27%              |
| Total Infections               | 27,054                 | 19,735              | 7,319            | 27%              |
| **C. Number of Chronic Infections by Age at Acquisition of Infection (Future burden)** |                        |                     |                  |                  |
| Perinatal Infection            | 106                    | 106                 | 0                | 0%               |
| Early Childhood Infection      | 4,021                  | 2,929               | 1,093            | 27%              |
| Late Infection                 | 811                    | 590                 | 220              | 27%              |
| Total Infections               | 4,937                  | 3,625               | 1,313            | 27%              |
| **D. Number of Deaths by Age at Acquisition of Infection (Future burden)** |                        |                     |                  |                  |
| Perinatal Infection            | 9                      | 9                   | 0                | 0%               |
| Early Childhood Infection      | 362                    | 264                 | 98               | 27%              |
| Late Infection                 | 89                     | 65                  | 24               | 27%              |
| Total Deaths                   | 460                    | 338                 | 123              | 27%              |

**Appendix: Input values**

- Prevalence HBsAg among women of child bearing age: 1.3
- Prevalence HBeAg among HBsAg-positive women of child bearing age: 12.5
- Prevalence of any marker of HBV infection among 5 year olds: 30
- Prevalence of any marker of HBV infection among 30+ year olds: 60
- Estimated Hepatitis B3 coverage: 28.6
- Estimated coverage with birth dose hepatitis B vaccine: 0
Questionnaires were administered only with the participant's assent; if discomfort was preventing response, the participant was offered the option of resuming the questionnaire following delivery.

**Conclusion**

The findings of this study indicate that HIV and syphilis were not present among intrapartum patients tested and that HBsAg prevalence was lower than for other general population groups assessed. A general screening program for HIV and syphilis does not appear cost-effective when the limited available resources are considered. However, HBsAg prevalence indicates hepatitis B is a pertinent public health issue and that routine surveillance among antepartum populations should be considered, particularly should HBeAg prevalence be assessed and found to be high. Future programming should include viral hepatitis in public health service announcements and awareness raising activities, potentially improving vaccination series completion. Intrapartum screening with rapid testing is feasible, acceptable, and suited for periodic surveillance activities as population shifts may introduce measurable changes in viral hepatitis prevalence, resulting in potential change in vaccination policy and practice. However, other models to disseminate testing, vaccine, and health information should also be developed to reach populations that do not access care centers and may be at greater risk for these infections.

**Abbreviations**

ACASI: audio computer-assisted self-interview; Anti-HBc: hepatitis B core antibody; DPT: diphtheria, pertussis, and tetanus; HBsAg: hepatitis B surface antigen; HbeAg: hepatitis B e antigen; HBV: hepatitis B virus; HCV: hepatitis C

### Table 4: Hepatitis B acquisition and future burden estimates for infants born in government maternity hospitals with 85% birth dose hepatitis B vaccine coverage vaccination programming in Kabul, Afghanistan.

|                      | Number Without Program | Number With Program | Number Prevented | Percent Reduction |
|----------------------|------------------------|---------------------|------------------|------------------|
| **A. Disease Events Prevented (Future burden)** |                       |                     |                  |                  |
| Total HBV infections | 27,054                 | 19,708              | 7,346            | 27%              |
| Acute symptomatic hepatitis B cases     | 5,400                  | 3,933               | 1,467            | 27%              |
| Chronic HBV infections | 4,937                 | 3,600               | 1,337            | 27%              |
| HBV-related deaths: |                       |                     |                  |                  |
| Acute hepatitis B | 23                     | 17                  | 6                | 27%              |
| Cirrhosis         | 268                    | 195                 | 73               | 27%              |
| Hepatocellular carcinoma | 170                  | 124                 | 46               | 27%              |
| Total Deaths      | 460                    | 336                 | 125              | 27%              |
| **B. Number of Infections by Age at Acquisition of Infection (Future burden)** |                       |                     |                  |                  |
| Perinatal Infection | 117                    | 90                  | 27               | 23%              |
| Early Childhood Infection | 13,410                | 9,766               | 3,643            | 27%              |
| Late Infection | 13,527                 | 9,852               | 3,675            | 27%              |
| Total Infections | 27,054                 | 19,708              | 7,346            | 27%              |
| **C. Number of Chronic Infections by Age at Acquisition of Infection (Future burden)** |                       |                     |                  |                  |
| Perinatal Infection | 109                    | 81                  | 24               | 23%              |
| Early Childhood Infection | 4,021                  | 2,929               | 1,093            | 27%              |
| Late Infection | 811                    | 590                 | 220              | 27%              |
| Total Infections | 4,937                  | 3,600               | 1,337            | 27%              |
| **D. Number of Deaths by Age at Acquisition of Infection (Future burden)** |                       |                     |                  |                  |
| Perinatal Infection | 9                      | 7                   | 2                | 23%              |
| Early Childhood Infection | 362                    | 264                 | 98               | 27%              |
| Late Infection | 89                     | 65                  | 24               | 27%              |
| Total Deaths | 460                    | 336                 | 125              | 27%              |
| **E. Number of HBV-Related Deaths in 2000 (Current burden)** |                       |                     |                  |                  |
| Acute hepatitis B | 166                    |                     |                  |                  |
| Cirrhosis | 1,130                   |                     |                  |                  |
| Hepatocellular carcinoma | 795                    |                     |                  |                  |
| Total Deaths | 2,090                   |                     |                  |                  |

Appendix. Input values

- Prevalance HBsAg among women of child bearing age: 1.3
- Prevalence HBeAg among HBsAg-positive women of child bearing age: 12.5
- Prevalence of any marker of HBV infection among 5 year olds: 30
- Prevalence of any marker of HBV infection among 30+ year olds: 60
- Estimated Hepatitis B3 coverage: 28.6
- Estimated coverage with birth dose hepatitis B vaccine: 85%
virus; anti-HCV: hepatitis C antibody; HIV: human immuno-
nodeficiency virus; STI: sexually transmitted infection; T.: 
Treponema; TP: Treponema pallidum; VDRL: Venereal Dis-
ease Research Laboratories

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
CT designed the study, analyzed the data, and assisted 
with manuscript preparation; MA assisted with study 
instrument design and pilot-testing, coordinated data col-
lection, and assisted with manuscript preparation; FA 
assisted with instrument design and data entry; SM 
assisted with study design and result interpretation; JS 
assisted with data collection coordination and manuscript 
preparation; PA assisted with instrument design, data col-
lection, and manuscript preparation; SASG assisted with 
study design and coordination of data collection; and SS 
assisted with study design and manuscript preparation. 
All authors read and approved the final manuscript.

Additional material

Additional file 1
CBBR Report. The data provided reflect the seroprevalence of the diseases of 
interest among screened blood donors in Afghanistan in 2006. 
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2334-8-119-S1.pdf]

Acknowledgements
The authors thank the Ministry of Public Health, the Kabul VCT, and the 
directors of the three maternity hospitals and deputy director of Malalai 
Hospital, Drs. Najia Tariq, Najeeba Seeamak, Nafisa Nassiry, and Hafiza 
Amarkhail and their staff for permitting and facilitating study activities. We 
acknowledge the efforts of our local advisory group (Dr. Malika Popol, Ms. 
Sheena Currie, Dr. Linda Bartlett, Dr. Kavitha Viswanathan, and Dr. Naqib 
Safi) on instrument design and translation. We thank Drs. Rana Graber 
Karak, Mark Appelbaum, J. Allen McCutchan, and Francis Mahoney for their 
guidance on result interpretation. Last, we thank the participants for their 
time and trust.

Financial Support: This study was funded by the Fogarty International 
Center of the United States National Institutes of Health 
(1KO1TW007408-01). Hepatitis B, HIV, and syphilis rapid test kits were 
donated by the Global Fund Management Unit of the Ministry of Public 
Health through funding from the Global Fund for AIDS, Malaria, and Tuber-
culosus and hepatitis C and all confirmatory test kits were donated by U.S. 
Health through funding from the Global Fund for AIDS, Malaria, and Tuber-

References
1. al-Owais A, al-Suwaidi K, Amiri N, Carter AO, Hossain MM, Sheek-
Hussein MP. Use of existing data for public health planning: a study of the prevalence of hepatitis B surface antigen and 
core antibody in Al Ain Medical District, United Arab Emir-
ates. Bull World Health Organ 2000, 78:1324-9.

2. Fabiani M, Fylkesnes K, Nattabi B, Ayella EO, Deichl E: Evaluating 
two adjustment methods to extrapolate HIV prevalence from 
pregnancy data to a general female population in 
sub-Saharan Africa. AIDS 2003, 17:399-403.

3. Saphonn V, Hor LB, Ly SP, Chhuon S, Saidel T, Detels R: How well 
do antenatal clinic (ANC) attendees represent the general 
population? A comparison of HIV prevalence from ANC 
sentinel surveillance sites with a population-based survey of 
women aged 15-49 in Cambodia. Int J Epidemiol 2002, 
31:449-55.

4. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratkachorn P, West 
Dj, Poerschke G: Protective efficacy of hepatitis B vaccine 
without HBIG in infants of HBsAg-positive carrier mothers 
in Thailand. Vaccine 2002, 20:3739-43.

5. Department of Vaccines and Biologicals, World Health Organization: 
Introduction of hepatitis B vaccine into childhood immuniza-
tion services. Management guidelines, including information 
for health workers and parents. World Health Organization, 
Geneva; 2001.

6. Vryheid RE, Kane MA, Muller N, Schatz GC, Bezaheb S: Infant and 
adolescent hepatitis B immunization up to 1999: a global 
overview. Vaccine 2000, 19:1026-37.

7. Chauvin P, Eksa D, Plotkin SA: The cost of not implementing 
routine neonates immunization programmes in HBsAg high 
prevalence countries. Vaccine 2002, 20:2848-2850.

8. Central Blood Bank: Report of Testing of Blood Donors from 
March–December, 2006. Ministry of Public Health, Kabul; 2006.

9. Ministry of Public Health, Indian Institute of Health Management 
Research/Johns Hopkins Bloomberg School of Public Health: 
National Risk and Vulnerability Assessment. 2006 [http://cso-
af.net/nrva2005/main.php]. Ministry of Public Health. Kabul, Afghani-
stan Accessed June 5, 2008

10. Quddus A, Luby SP, Jamal Z, Jafar T: Prevalence of hepatitis B 
among Afghan refugees living in Balochistan, Pakistan. Int J 
Infect Dis 2006, 10:242-7.

11. Pourkarim MR, Zandi K, Davani NA, Pourkarim HR, Amini-Bavil-Oly-
see S: An aberrant high prevalence of hepatitis B infection 
among Afghans residing in one of the Bushehr refugee 
camps (Dalaki camp) in the southwest of Iran. Int J Infect Dis 
2008, 12:101-2.

12. Central Statistics Office: Annual Report. Kabul-Afghanistan [http:// 
www.cso.gov.af/Census/census.htm]. Accessed June 5, 2008

13. World Health Organization: Hepatitis B surface antigen assays: 
operational characteristics. Phase 1. WHO, Geneva; 2001.

14. Standard Diagnostics: Rapid test: hepatitis information sheet. 
[http://standardi.com/html_e/mn03/mn03_01_00.asp?intId=2]

15. Dao H, Mofenson LM, Elpini R, Gilks CF, Barnhart M, Bolu O, Shaffer N: 
International recommendations on antiretroviral drugs for 
treatment of HIV-infected women and prevention of 
mother-to-child HIV transmission in resource-limited set-
tings: 2006 update. Am J Obstet Gynecol 2007, 197(3 Suppl):S42-55.

16. Mast E, Mahoney F, Kane MA, Margolis HS: Hepatitis B vaccine. In 
Vaccines 4th edition. Edited by: Plotkin SA, Orenstein WA. W.B. 
Saunders Company. Philadelphia, PA; 2004:399-338.

17. CDC Advanced Immunization Management: AIM e-Learning: Con-
considerations for Introduction of new and under-utilized vac-
cines. [http://aim.path.org/en/vaccines/hepb/assessBurden/model/
2.html]. Accessed November 8, 2007

18. Prakash C, Sharma RS, Bhatia R, Verghese T, Datta KK: Prevalence 
of North India of hepatitis B carrier state amongst pregnant 
women. Southeast Asian J Trop Med Public Health 1998, 
29:80-4.

19. Nayak NC, Panda SK, Zuckerman AJ, Bhan MK, Guha DK: Dynamics 
and impact of perinatal transmission of hepatitis B virus in 
North India. J Med Virol 1987, 21:137-45.

20. Mittal SK, Rao S, Rastogi A, Aggarwal V, Kumari S: Hepatitis B – 
potential of perinatal transmission in India. Trp Gastroenterol 
1996, 17:190-2.

21. World Health Organization: Introduction of Hepatitis B Vaccine 
in Afghanistan. WHO, Kabul; 2005.

http://www.biomedcentral.com/1471-2334/8/119
23. Joint United Nations Programme on HIV/AIDS: Afghanistan. [http://www.unaids.org/en/Regions_Countries/Countries/afghanistan.asp]. Accessed February 20, 2008.

24. Wang CS, Chang TT, Yao WJ, Chou P: Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am J Trop Med Hyg 2002, 66:389-93.

25. Khan AJ, Luby SP, Fikree F, Karim A, Obaid S, Dellawala S, Mirza S, Malik T, Fisher-Hoch S, McCormick JB: Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull World Health Organ 2000, 78:956-63.

26. Hargreaves JR, Glynn JR: Educational attainment and HIV-1 infection in developing countries: a systematic review. Trop Med Int Health 2002, 7:489-98.

27. Tareen S, Eslick GD, Kam EP, Byles JE, Durrani AB, Maree SM: High prevalence of hepatitis B virus (HBV) among male blood donors in a developing country: urgent need for systematic screening. Scand J Infect Dis 2002, 34:712-3.

28. Akhtar S, Younus M, Adil S, Hassan F, Jafri SH: Epidemiologic study of chronic hepatitis B virus infection in male volunteer blood donors in Karachi, Pakistan. BMC Gastroenterol 2005, 5:26.

29. Jensen L, Helmann C, Smith E, Wantzin P, Peitersen B, Weber T, Krogsgaard K: Efficacy of selective antenatal screening for hepatitis B among pregnant women in Denmark: is selective screening still an acceptable strategy in a low-endemicity country? Scand J Infect Dis 2003, 35:378-82.

30. Connor N, Roberts J, Nicoll A: Strategic options for antenatal screening for syphilis in the United Kingdom: a cost-effectiveness analysis. J Med Screen 2000, 7:7-13.

31. Graves N, Walker DG, McDonald AM, Kaldor JM, Ziegler JB: Would universal antenatal screening for HIV infection be cost-effective in a setting of very low prevalence? Modelling the data for Australia. J Infect Dis 2004, 190:166-74.

32. Kane MA: Hepatitis B control through immunization. In Viral hepatitis and liver disease Edited by: Rizzetto M, Purcell RH, Gerin JL, Vermin G. Turin, Italy Edizioni Minerva Medica:638-642.

33. United Nations High Commissioner for Refugees: Return to Afghanistan – Still Major Challenges Ahead. [http://www.unhcr.org/afghan.html]. Accessed June 5, 2008.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2334/8/119/prepub

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp